AlveoGene’s Mission is to transform respiratory disease outcomes using inhaled gene therapy.
Our #InGenuiTy® platform enables us to deliver our proprietary self-inactivating lentiviral vector based products directly to the lung via nebulisation treating disease locally, efficiently, and safely where it’s clinical impact and patient benefit can be the greatest.
We focus on respiratory diseases of high value and unmet medical need, developing first-in-class and best-in-class products including Alpha-1 Antitrypsin Deficiency (AATD), Neonatal Profound Surfactant Protein Deficiencies (SP-B and ABCA3), and Idiopathic pulmonary Fibrosis (IPF).
New treatment paradigms for respiratory diseases are highly prized with M&A or IPOs at very attractive valuations possible, the most recent direct AlveoGene comparator being Sanofi’s acquisition of Inhibrx for $1.6Bn.
With our lead asset AVG-001 indicated for AATD, we estimate we could achieve near term sales of c£500M+ rising to potentially £2.5Bn over time. Additionally, we believe we could achieve market approval for SP-B and ABCA3 products within 3 years and estimate initial sales >£50m pa, rising to potentially >£100m pa per product. The current market for IPF is >$6Bn.
We have shown single dose efficacy, long-term durability of effect (critically retaining an ability to re-dose if required), combined with the convenience of administration, transforming the current standard of care of frequent IV bolus injections, or providing therapeutic solutions for diseases that currently do not exist.
Importantly the InGenuiTy® platform’s potential has been validated in a prior deal with Boehringer Ingelheim for Cystic Fibrosis (CF) which is now entering the clinic. Given the identical vector backbone, this provides significant risk mitigation in CMC, quality and regulatory matters, supporting accelerated approvals of subsequent AlveoGene products.
AlveoGene’s Executive Chair David Hipkiss will be attending Bio€equity 2024 and will be presenting the latest developments of the Company.
For more information and to arrange a meeting, please contact us on [email protected]